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Native type I heat-labile toxins (LTs) produced by enterotoxigenic Escherichia coli (ETEC)
strains exert strong adjuvant effects on both antibody and T cell responses to soluble
and particulate antigens following co-administration via mucosal routes. However, inher-
ent enterotoxicity and neurotoxicity (following intra-nasal delivery) had reduced the interest
in the use of these toxins as mucosal adjuvants. LTs can also behave as powerful and safe
adjuvants following delivery via parenteral routes, particularly for activation of cytotoxic
lymphocytes. In the present study, we evaluated the adjuvant effects of a new natural LT
polymorphic form (LT2), after delivery via intradermal (i.d.) and subcutaneous (s.c.) routes,
with regard to both antibody and T cell responses. A recombinant HIV-1 p24 protein was
employed as a model antigen for determination of antigen-specific immune responses
while the reference LT (LT1), produced by the ETEC H10407 strain, and a non-toxigenic
LT form (LTK63) were employed as previously characterized LT types. LT-treated mice
submitted to a four dose-base immunization regimen elicited similar p24-specific serum
IgG responses and CD4+ T cell activation. Nonetheless, mice immunized with LT1 or LT2
induced higher numbers of antigen-specific CD8+ T cells and in vivo cytotoxic responses
compared to mice immunized with the non-toxic LT derivative. These effects were corre-
lated with stronger activation of local dendritic cell populations. In addition, mice immunized
with LT1 and LT2, but not with LTK63, via s.c. or i.d. routes developed local inflammatory
reactions. Altogether, the present results confirmed that the two most prevalent natural
polymorphic LT variants (LT1 or LT2) display similar and strong adjuvant effects for subunit
vaccines administered via i.d. or s.c. routes.
Keywords: vaccines, adjuvants, heat-labile toxin, HIV-1, p24, intradermal immunization, cytotoxicT cell response
INTRODUCTION
Type I heat-labile toxins (LTs) produced by some enterotoxi-
genic Escherichia coli (ETEC) strains belong to a family of struc-
turally and immunologically related enterotoxins associated with
traveler’s diarrhea (1). LTs consist of one A subunit (LTA) non-
covalently bound to the pentameric B subunit (LTB), which is
formed by the union of five identical polypeptides. The A subunit
has ADP ribosyltransferase activity, and the B subunit targets the
protein to glycosphingolipid receptors on the surface of eukaryotic
cells (e.g., GM1 ganglioside). After receptor binding, the toxin is
internalized and cleaved proteolytically, and the active A1 domain
is released into the cytoplasm, resulting in the permanent activa-
tion of the Gsα component of adenylate cyclase. The enhanced
3′,5′-cyclic monophosphate (cAMP) levels promote massive ion
and water losses from the enterocytes to the intestinal lumen,
leading to diarrhea (1).
In addition to their pivotal role in the etiology of ETEC-
associated secretory diarrhea, LTs have attracted considerable
interest due to their strong adjuvant effects observed after co-
administration of the toxin with soluble or particulate antigens
via mucosal (2–9) or transcutaneous routes (9–11). To increase
the safety of LTs as mucosal adjuvants, mutant forms have been
generated, including LTK63, which is devoid of ADP-ribosylation
activity but partially preserves the adjuvant effects (3, 12–15).
However, clinical trial results were disappointing due either to the
induction of unacceptable side effects (transient facial paralysis)
after intra-nasal administration of LTK63 or to reduced adjuvant
effects in subjects immunized with LT-adjuvanted adhesive vaccine
patches (10, 11, 15).
Recently, a significant degree of genetic diversity has been
detected in the LTs produced by ETEC strains isolated from symp-
tomatic and asymptomatic subjects in Brazil. Sixteen LT types
were identified, including LT1, expressed by the reference ETEC
H10407 strain and several other ETEC strains of different serotype
groups (16). Another LT type, named LT2, represents the second
most prevalent natural LT form found among LT-producing ETEC
strains. DNA sequencing revealed that LT2 has six polymorphic
sites compared to the LT1: five in the A subunit (S190L, G196D,
K213E, S224T, and N238D) and one in the B subunit (T75A)
(16). LT2 showed both ADP-ribosylation activity and binding
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to host cell receptors but showed different immunological fea-
tures compared with the reference LT, particularly with regard
to the humoral adjuvant effects by transcutaneous administra-
tion (9). The same LT natural variant has also been detected
in an ETEC strain isolated from a diarrheic tourist in Japan,
which suggest that this LT-encoding gene may have a widespread
occurrence (17).
In the present study, we further investigated the immunological
features of LT2 in comparison with other known LT forms, includ-
ing LT1 and LTK63, particularly with regard to the adjuvant effects
for both humoral (antibody) and cellular (T cell) responses elicited
in mice immunized via parenteral routes (intradermal and subcu-
taneous) with co-administered recombinant HIV-1 p24 protein as
a model antigen.
MATERIALS AND METHODS
CLONING, EXPRESSION, AND PURIFICATION OF THE RECOMBINANT
HIV-1 p24 PROTEIN
The coding sequence for the HIV-1 p24 antigen was ampli-
fied from the pHXB2 plasmid (GenBank Accession Num-
ber K03455) (18) using the following primers: sense 5′-
CGATG∧CTAGCATGCAGAACATCCAGGGGCA-3′ and anti-
sense 5′-GTG∧AATTCTCAAGCCAAAACTCTTGCCTTA-3′. The
amplified fragment was inserted in frame into the pET28b expres-
sion vector (Novagen) between the NheI and EcoRI restric-
tion sites (underlined). BL21(DE3) strain E. coli (Invitrogen)
were transformed with the expression vector, and after it was
carried out screening for positive clones by restriction analy-
sis and DNA sequencing. Induction of the recombinant protein
was achieved by addition of isopropyl-β-d-thiogalactopyranoside
(IPTG) to the culture for 4 h at 37°C under aeration. The
recombinant p24 with an N-terminal histidine tag was puri-
fied using a HisTrap™ HP column (GE Healthcare Bio-
Sciences Corp). The protein concentration was determined using
the BCA assay (Pierce), and purity was monitored in 15%
polyacrylamide gel electrophoresis (SDS-PAGE). Endotoxin was
removed after successive washing steps with 1% Triton X-114
(19). Endotoxin levels of the preparations, determined by Chro-
mogenic Limulus Amebocyte Lysate assay (LAL) (Cambrex Bio-
sciences), were equal to 0.1 EU of endotoxin per 1µg of purified
protein.
CLONING, EXPRESSION, AND PURIFICATION OF LTs
Construction of the pML19, pML21, and pLTK63 plasmids encod-
ing the LT1 (GenBank Accession Number GI 408994), LT2, and
LTK63 toxins, respectively, was carried out as previously described
(9) and using data available at GenBank for LT1 and showed by
Imamura and coworkers (17) and Pizza and coworkers (12). We
constructed LTK63, in which serine at position 63 of the A subunit
was replaced by lysine, at the background of LT1. The LT2 natural
variant has five polymorphic sites in the A subunit (S190L, G196D,
K213E, S224T, and N238D) and one in the B subunit (T75A) com-
pared to LT1 (9, 16). Toxin purification by affinity chromatography
on immobilized d-galactose columns (Pierce) was described pre-
viously (9). Endotoxin levels of the preparations determined by
LAL assay were equal or lower to 0.2 EU of endotoxin per 1µg of
purified protein.
SDS-PAGE AND IMMUNOBLOT ANALYSES
Proteins separated on 15% polyacrylamide gels were stained with
Coomassie Blue R250 or transferred to nitrocellulose membranes.
Immunoblots for the detection of the p24 protein were carried out
using standard procedures with anti-HIV p24 rabbit serum (NIH
AIDS catalog no. 4250) diluted in 1% bovine serum albumin (BSA)
in PBS (block solution).
FUNCTIONAL CHARACTERIZATION OF PURIFIED LT
Determination of the intracellular adenosine cAMP levels was
performed using the Y-1 adrenal tumor cell line, as previously
described (20). The GM1-ELISA was carried out using standard
procedures (21). The binding of LT to mouse Y-1 cells was deter-
mined using 1µg of the tested toxin at 4°C for 1 h in DMEM
medium. Treated cells were washed with PBS containing 1% fetal
bovine serum and incubated with mouse anti-LT serum. After
30 min, the cells were stained with a FITC-conjugated anti-mouse
IgG antibody (Invitrogen) and analyzed by flow cytometry (FACS
Calibur, Becton Dickinson, Mountain View, CA, USA). The data
were analyzed using the FlowJo program (Tree Star).
TRANSFECTION OF CELLS AND IMMUNOFLUORESCENCE ANALYSES
The specificity of the antibodies raised in mice immunized with
the recombinant HIV-1 p24 protein was determined with A3.01
cells transfected with the pHXB2 plasmid encoding the complete
genome of HIV-1 (18). Transfection with the pHXB2 plasmid
encoding the complete HIV-1 genome was carried out with poly-
ethylenimine (PEI) (1 mg/mL) (Polysciences) for 30 min at 37°C
in a 5% CO2 atmosphere. After 7–8 days, transfected cells were
harvested, added to 96-well plates (Nunc), washed twice with
PBS, and fixed with methanol at room temperature. The plates
were then incubated with blocking solution (0.2% Tween-20, 3%
skim milk in PBS) for 30 min at 37°C before being probed with
primary antibodies for subsequent immunofluorescence labeling.
The plates were exposed to primary antibodies (sera derived from
mice immunized with the recombinant p24 protein plus Complete
Freund’s Adjuvant or PBS) diluted to 1:500 for 1 h at 37°C. After
two washings with PBS, the plates were incubated with FITC-
labeled goat anti-mouse IgG (Invitrogen) plus 1µg/mL DAPI
(Invitrogen) for 1 h at 37°C. Cells were washed twice with PBS,
dried at room temperature, and visualized with an immunoflu-
orescence inverted microscope (Nikon) equipped with a digital
camera.
MIGRATION OF DENDRITIC CELLS TO DRAINING LYMPH NODES AND
IN VIVO ACTIVATION
BALB/c mice were inoculated with intradermal (i.d.) or subcu-
taneous (s.c.) injections of 1µg of LT1, LT2, or LTK63, and the
inguinal lymph nodes (ILNs) were removed 24 h after the immu-
nization. Pooled ILNs cells were harvested after tissue homoge-
nization with a glass homogenizer and extensive washing with 2%
fetal bovine serum (FBS)/PBS. Cells were plated at a concentration
of 5× 106 cells per well and stained with anti-CD11c and anti-I-
Ad (MHC-II), plus anti-H-2Kd (MHC-I), anti-CCR7, anti-CD80,
anti-CD86, or anti-CD40 conjugated antibodies (BD Biosciences).
Labeled cells were suspended in PBS containing 2% FBS and ana-
lyzed (1.5× 106 events/sample) in a cell cytometer (FACSCanto,
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Becton, Dickinson and Company). The data were analyzed using
FlowJo software (Tree Star) gated on the CD11c+/MHC-II+ cells.
Results were measured in pooled ILNs cells harvested from mice
subjected to the different treatments (n= 5 per group). All samples
were tested in duplicates, and each tested condition was repeated
independently twice.
MICE AND IMMUNIZATION PROTOCOLS
Specific pathogen-free BALB/c mice (8–15 weeks old) were sup-
plied by the Isogenic Mouse Breeding Facility of the Department
of Parasitology, Institute of Biomedical Sciences, University of São
Paulo (USP). All animal handling was carried out in accordance
with the principles of the Brazilian code for the use of labora-
tory animals and was approved by the committee on the ethical
use of laboratory animals at the Institute of Biomedical Sciences,
USP. Mice were immunized with 20 or 100µL aliquots adminis-
tered by i.d. or s.c. injections, respectively, on the dorsal surface
on days 0, 14, 28, and 42. For the i.d. injections, the mice were
partially shaved on the dorsum 1 day before injection. Purified
p24 protein was injected at a dose of 20µg/animal admixed with
1µg of LT1, LT2, or LTK63. Control groups received sterile PBS or
non-adjuvanted p24 protein. Serum samples were collected 1 day
before each immunization for ELISA assays. Animals were sacri-
ficed 2 weeks after the last immunization for the determination of
the CD4+ and CD8+ T cell responses and the in vivo CTL activ-
ity. The experiments were performed independently three or two
times, respectively with n= 5 animals per immunization group as
indicated on respective legend.
LOCAL SKIN INFLAMMATORY EFFECTS
BALB/c mice were i.d. inoculated with a single dose of 1µg of
LTs per animal/20µL at previously shaved dorsal caudal area.
Local skin reactions were inspected regularly for redness, edema,
and swelling for 10 days after injection. The diameter of swelling
was measured with a caliper. The experiments were performed
independently twice with n= 5 animals per immunization group.
DETECTION OF ANTI-p24 SERUM ANTIBODY RESPONSES
p24-specific ELISA was carried out with 96-well Maxisorp plates
(Nunc International) coated with purified p24 protein (5µg/mL)
diluted in PBS at pH 7.5 and incubated overnight at 4°C. Serum
samples from immunized mice, anti-HIV p24 rabbit serum (NIH
AIDS catalog no. 4250) or serum from an HIV-infected individual
(NIH AIDS catalog no. 192) was serially diluted (twofold) in block-
ing solution and added to the wells for 1 h at 37°C. Reactions were
performed with diluted horseradish peroxidase-conjugated rabbit
anti-mouse immunoglobulin (total IgG, IgG1, or IgG2a) (Sigma
and Southern Biotech), anti-human IgG antibody (Southern
Biotech), or rabbit anti-IgG antibody.
DETECTION OF SECRETED CYTOKINES
Secreted cytokines were measured using the ELISA BD OptEIA™
kit (BD Biosciences) with the supernatants of cultured spleen cells
harvested from immunized mice. The cells were stimulated with
a synthetic peptide (GenScript) corresponding to the I-Ad CD4+
T cell-specific (AMQMLKETINEEAAE) epitope of the HIV-1 p24
protein at a final concentration of 5µg/mL for 48 h at 37°C in a
5% CO2 atmosphere. After stimulation, the supernatants were
collected for determination of the IFN-γ and IL-5 concentra-
tions. All samples were tested in duplicate, and each immunization
experiment was repeated independently twice.
ELISPOT ASSAY
The IFNγ-ELISPOT was performed essentially as described earlier
(22). Spleen cells collected from immunized animals were diluted
in complete media, plated at a concentration of 5× 105 cells per
well, and incubated for 24 h at 37°C in a 5% CO2 atmosphere in
medium with and without the synthetic peptide corresponding to
the major H-2Kd CD8+ T cell-specific (AMQMLKETI) p24 epi-
tope at a final concentration of 2.5µg/mL. All samples were tested
in duplicate, and each immunization experiment was repeated
independently three times.
IN VIVO CTL ASSAYS
The in vivo CTL responses were determined as previously
described (22). Briefly, splenocytes collected from naive BALB/c
mice were stained with 0.5µM (CFSElow) or 5µM (CFSEhigh) car-
boxyfluorescein diacetate succinimidyl ester (CFSE) (Invitrogen
Molecular Probes). The CFSEhigh cells were pulsed for 40 min at
37°C with 1µM of the synthetic p24 CD8+ T cell-specific peptide.
Subsequently, aliquots containing equal amounts of CFSElow and
CFSEhigh cells (2× 107 cells) were intravenously injected into mice
previously immunized with the different vaccine formulations and
naïve control mice. Twenty hours later, the numbers of CFSElow
and CFSEhigh cells were determined in the spleens of the recipient
mice using flow cytometry. The percentage of specific cell lysis was
determined for each animal using the formula 100− [(% CFSEhigh
in immunized mice/% CFSElow in immunized mice)/(% CFSEhigh
in naïve mice/% CFSElow in naïve mice)]× 100%. All samples
were tested in duplicate, and each immunization experiment was
repeated independently twice.
STATISTICAL ANALYSES
One-way ANOVA followed by Tukey’s HSD test was used to
compare the differences between the mean values of the immu-
nization groups. Differences with p≤ 0.05 were considered statis-
tically significant. The statistical analyses were performed with the
animals belonging to each immunization group (n= 4–5) with
independent experiments.
RESULTS
GENERATION OF THE RECOMBINANT p24
A soluble recombinant form of the HIV-1 p24 protein was gener-
ated in bacterial cells purified by nickel affinity chromatography
(Figure 1A). The recombinant protein retained the antigenicity
of the native viral protein, as demonstrated in Western blots and
ELISAs developed with reference serum samples collected from a
rabbit immunized with purified p24 protein and an HIV-infected
subject (Figures 1B,D). The recombinant protein p24 were at least
95% pure (Figure 1C) and contained 0.1 EU of endotoxin per
microgram of purified protein. Additionally, anti-p24 antibodies
raised in mice immunized with the recombinant p24 recognized
the native virus protein expressed by A3.01 cells transfected with
a plasmid vector encoding all virus proteins (Figure 1E).
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FIGURE 1 | Purification and immunological characterization of the
recombinant HIV-1 p24 protein. (A) SDS-PAGE analysis of whole-cell
extracts of the recombinant bacterial strain and purified p24 protein.
Samples: lane 1, whole-cell extract of the E. coli BL21(DE3) strain
transformed with the plasmid encoding the recombinant p24 cultured
without addition of the inducer; lane 2, whole-cell extract of the E. coli
BL21(DE3) strain transformed with the plasmid encoding the recombinant
p24 cultured after addition of the inducer; lane 3, purified p24 after affinity
chromatography in a nickel-containing resin. MW, PageRuler™ pre-stained
Protein Ladder (Fermentas). One to two lines were loaded with 10µL of
whole-cell extract of E. coli at D.O.600nm 4 before (line 1) or after (line 2) IPTG
addition or 3µg of purified p24 protein (line 3); (B) Immunoblot developed
with p24-specific rabbit polyclonal serum. Protein samples were the same
as described above. (C) SDS-PAGE analysis of purified p24 protein not
completely separated on 15% polyacrylamide gels. (D) Antigenicity of the
recombinant p24. The protein was employed as solid phase-bound antigen
in ELISA plates developed with sera obtained from an HIV-1 infected subject
(open squares) or from a rabbit immunized with recombinant p24 (closed
squares). (E) Antibodies raised in mice immunized with the recombinant
p24 recognize the native viral protein. Cells of the A3.01 lineage were
transfected with the pHXB2 vector encoding the complete HIV-1 genome.
After 7 days, the cells were fixed and incubated with serum from mice
immunized with p24 combined with Freund’s adjuvant (lower panel series)
or PBS (upper panel series), at a final dilution of 1:500. Cells were labeled
with FITC-conjugated anti-mouse IgG antibody and DAPI. The experiments
were performed twice showing the same results.
GENERATION AND BIOLOGICAL CHARACTERIZATION OF LTs
The three LT derivatives (LT1, LT2, LTK63) were expressed and
purified from recombinant E. coli strains. The recombinant tox-
ins displayed similar electrophoretic motility, binding to purified
GM1 receptor and Y-1 cells (Figures 2A,C,D). In addition, LT1
and LT2 displayed similar enzymatic activity, as demonstrated by
the increase in intracellular cAMP in treated Y-1 cells (Figure 2B).
Mice inoculated by the i.d. route with LT1 and LT2 developed
intense local inflammatory reactions measured by edema forma-
tion and induration at the inoculation site as early as 24 h post
administration and persisted for more than 10 days. In contrast,
mice inoculated with LTK63 induced a slight swelling reaction at
the injection site detected at 48 h after inoculation and vanished
8 days later (Figure 2E). Similar reactions were observed in mice
inoculated via the s.c. route (data not shown).
ACTIVATION OF MIGRATORY BEHAVIOR AND IN VIVO ACTIVATION OF
DC IN LT-INOCULATED MICE
We also tested the in vivo effects of the LTs on the behavior of
CD11c+/MHC-II+ dendritic cells (DCs) after administration via
the s.c. and i.d. routes. As shown in Figure 3, 24 h after a sin-
gle i.d. administration of the tested LTs, the numbers of DCs at
the ILNs were significantly higher among LT-treated mice than
PBS-treated animals. Mice inoculated with the non-toxic LTK63
showed a lower number of CD11c+/MHC-II+ cells in the draining
lymph nodes than mice inoculated with LT1 or LT2 (Figure 3A).
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FIGURE 2 | Purification and functional characterization of the
recombinant LT derivatives. (A) SDS-PAGE of the purified recombinant
LT (2µg/lane). Samples: lane 1, LT1; lane 2, LT2; lane 3, LTK63; and MW,
PageRuler™ Unstained Protein Ladder (Fermentas). (B) In vitro cAMP
accumulation in Y-1 cells exposed to trypsin-activated LT1, LT2, or LTK63
for different time periods. (C) Binding of the purified LTs to Y-1 cells. Cells
were incubated with LT1, LT2, or LTK63 for 1 h and labeled with mouse
anti-LT and FITC-conjugated anti-mouse IgG antibodies before analysis of
emitted fluorescence in a flow cytometer. Samples: LT1 (dotted line); LT2
(black line), and LTK63 (gray line). Untreated Y-1 cells are indicated by the
dashed line on the left side of the figure. (D) Receptor binding activities of
the purified LT derivatives in GM1-ELISA. Reactions were developed with
mouse anti-LT serum and peroxidase-conjugated anti-mouse IgG antibody.
(E) Local edema formation in BALB/c mice (n=5) after i.d. injection of 1µg
of the test LT forms. The experiment was independently performed three
times.
Similar results were observed in mice immunized via the s.c. route
(data not shown). However, no significant difference in the expres-
sion of CCR7, a marker associated with DC migratory behavior
(23), was observed in mice treated with the LTs (Figure 3B). We
also measured the in vivo activation of CD11c+/MHC-II+ cells in
ILNs after inoculation of the different LTs. Although no significant
increase in the expression of MHC-I and CD40 (Figures 3C,D) was
detected in mice treated with the LT derivatives, CD11c+/MHC-
II+ cells harvested from mice inoculated with LT1 or LT2 showed
an enhanced expression of CD80 and CD86 compared to the
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FIGURE 3 | Effects on DC migratory behavior and the expression of
activation markers after the administration of the LT derivatives via
the i.d. route in BALB/c mice. Draining ILNs were collected 24 h after
injection of 1µg of the tested LT derivatives, after which
CD11c+/MHC-II+ cells were analyzed in a flow cytometer. (A) Total
number of CD11c+/MHC-II+ cells detected after injection of the tested
LT; (B–F) Median fluorescence intensity of CD11c+/MHC-II+ cells labeled
for (B) CCR7, (C) MHC-I, (D) CD40, (E) CD80, or (F) CD86 markers. The
expression of surface markers was analyzed by acquiring 3×106 events.
Asterisks indicate statistically significant differences (*p< 0.05) with
regard to the control mouse group (PBS). Results are expressed as
means±SD of two experiments performed independently with pooled
of ILNs cells harvested from mice (n=5) subjected to the different
treatments.
control group (Figures 3E,F). Similar results were also observed
in mice inoculated via the s.c. route (data not shown).
ADJUVANT EFFECTS OF LT DERIVATIVES ON B CELLS AND CD4+ T
LYMPHOCYTES IN MICE IMMUNIZED VIA PARENTERAL ROUTES
Titers of p24-specific serum IgG were increased in mice immu-
nized via s.c. and i.d. routes with the recombinant p24 protein
admixed with LT1, LT2, or LTK63. No statistically significant dif-
ferences were observed in the anti-p24 antibody titers in mice
treated with LT1 or LT2 following either i.d. or s.c. immunization
(Figures 4A,B). However, lower anti-p24 IgG titers were detected
in mice immunized with i.d. injections of LTK63 compared with
mice immunized with LT1 or LT2 (Figure 4A). Analysis of the
IgG subclass responses elicited in LT-vaccinated mice showed that,
after four vaccine doses, mixed IgG1/IgG2a response was observed
among animals regardless of the route of immunization. How-
ever, higher IgG1/IgG2a ratios were detected in mice immunized
via s.c. route compared to mice immunized via the i.d. route
(Figures 4C,D).
Immune response evaluations of cytokine profiles showed that
splenic CD4+ T cells of mice immunized with i.d. injections of
the LT derivatives secreted similar levels of IFN-γ and undetectable
amounts of IL-5 (Figure 4E). Nonetheless, following s.c. vaccina-
tion, mice immunized with LTK63 showed higher levels of IFN-γ
secretion by CD4+ T cells than mice treated with LT1 or LT2,
whereas differences in the IL-5 levels were not observed between
any of the immunization groups (Figure 4F). IL-4 was not detected
in the culture supernatants of splenic cells from mice vaccinated
via either the i.d. or the s.c. route (data not shown). Additionally, all
LT forms increased IFN-γ levels compared with p24 administered
alone, following either i.d. or s.c. immunization. These results,
together with the IgG subclass findings, show that LT derivatives
modulate the anti-p24 response toward a more biased Th2 profile
when administered via the s.c. route compared to mice immunized
via the i.d. route.
CD8+ T CELL ADJUVANT EFFECTS OF LT DERIVATIVES IN MICE
IMMUNIZED VIA PARENTERAL ROUTES
Adjuvant effects on CD8+ T cells were measured in spleen cells har-
vested 2 weeks after the last immunization dose. IFNγ-ELISPOT
results showed that mice immunized with the LT derivatives
induced strong activation of p24-specific CD8+ T cells, whereas
no significant response was detected in mice immunized with
non-adjuvanted p24. Mice immunized with LT2 by the i.d. route
showed statistically higher CD8+ T cell responses compared to
mice immunized with LT1 or LTK63 (Figure 5A). In contrast, mice
immunized with LT2 via the s.c. route showed similar CD8+ T cell
responses compared to mice immunized with LT1 (Figure 5B).
The results also showed that the LT derivatives enhanced in vivo
CTL responses after administration either i.d. or s.c. immuniza-
tion. Nonetheless, mice immunized with LTK63 mounted signif-
icantly lower in vivo CTL responses than mice immunized with
LT1 and LT2 (Figures 5C,D).
DISCUSSION
In the present study, we investigated the adjuvant effects of a
natural LT form (LT2) after administration of a soluble anti-
gen (a recombinant HIV p24 protein) administered via i.d. and
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FIGURE 4 | Antigen-specific serum IgG and secreted cytokine responses
in mice immunized with p24 adjuvanted with LT derivatives via i.d. or
s.c. routes. BALB/c mice were immunized with four doses of p24 admixed
with LT1, LT2, or LTK63. Two weeks after each dose, mice were bled to obtain
p24-specific serum. A control group was immunized with purified p24 without
adjuvant. (A,B) Anti-24 IgG titers were measured in mice immunized via i.d.
(A) or s.c. (B) routes. (C,D) IgG subclass responses elicited in mice
immunized via i.d. (C) or s.c. (D) routes after the fourth dose. The numbers on
the top of the columns represent the IgG1 (dotted bars)/IgG2a (black bars)
ratio for each group. (E,F) IFN-γ (white bars) and IL-5 (black bars) secreted by
spleen cells collected from mice immunized via i.d. (E) or s.c. (F) routes
2 weeks after the last immunization. Spleen cells were stimulated in vitro for
20 h with a synthetic peptide (AMQMLKETINEEAAE) encompassing the
immunodominant p24-specific MHC-II-restricted CD4+ T cell-specific epitope.
Results are expressed as means±SD (n=4–5 per immunization group) of
three (A–D) or two (E,F) experiments performed independently. Statistically
significant differences with regard to the p24-immunized mouse group are
indicated with asterisks above the columns. In brackets, comparisons were
carried out between different LT-treated groups. *p<0.05; **p<0.01;
***p<0.001.
s.c. routes to mice. The LT2 derivative has been detected in sev-
eral ETEC strains isolated from both diarrheic and asymptomatic
subjects representing the second most frequent LT polymorphic
variant found among clinical-derived ETEC strains (9, 16, 17). LT2
proved to be endowed with strong adjuvant effects similar to those
detected in mice immunized with the reference LT form (LT1)
and superior to those induced by LTK63 with respect to antigen-
specific serum antibody responses and activation of CD8+ T cell
and CTL responses. LT1 and LT2 also promoted the more efficient
in vivo activation of DC, as evaluated both by migration to local
lymph nodes and expression of co-stimulatory molecules (CD80
and CD86). Altogether, these data indicate that LT2 preserves both
the biological and immunological features of the reference LT1
toxin representing alternatives for vaccine adjuvants delivered via
s.c. and i.d. routes.
The adjuvant effects of LT have been intensively investigated
for more than three decades. Previous studies were carried out
with native or non-toxic derivatives of a reference LT form (LT1)
usually administered via mucosal routes (3, 6, 9, 20). The general
conclusion from these studies is that LT derivatives act as powerful
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FIGURE 5 | CD8+ T cell adjuvant effects of LT derivatives administered
via i.d. and s.c. routes. (A,B) IFN-γ ELISPOT assay carried out with
spleen cells of mice immunized with four doses of p24 adjuvanted with
LT1, LT2, or LTK63 or p24 non-adjuvanted. Spleen cells were harvested
from animals immunized via i.d. (A) or s.c. (B) routes 2 weeks after the last
vaccine dose. Cells were stimulated with a synthetic peptide
encompassing the p24 immunodominant MHC-I-restricted CD8+ T cell
epitope for detection of IFN-γ-secreting cells. Results are expressed as
means±SD (n= 4–5 per immunization group). Experiments were
performed independently three times. (C,D) In vivo CTL responses in mice
immunized with LT via i.d. (C) or s.c. (D) routes. Two weeks after the final
immunization, mice were injected with splenic syngeneic CFSE-labeled
cells pulsed with the AMQMLKETI peptide. The specific in vivo CTL
responses were determined 20 h later by the CFSEhigh/CFSElow cell ratios,
as described in the Section “Materials and Methods.” Results are
expressed as means±SD (n=4–5) of two experiments performed
independently. Statistically significant differences with regard to the
p24-immunized mouse group are indicated with asterisks above the
columns. In brackets, comparisons between different LT-treated groups.
*p<0.05; **p<0.01; ***p< 0.001.
adjuvants both for serum and mucosal antigen-specific antibody
responses and may lead to different T helper cell activation patterns
that may change according to the nature of the antigen, attenuat-
ing mutations, and administration route (2, 8, 24–30). Our results
based on the serum antibody responses induced in mice support
previous evidences indicating that the humoral adjuvant effects of
parenterally delivered LT are not dependent on the toxic activity
of the A subunit (4, 8, 31). Moreover, IgG subclass response and
cytokine secretion patterns of splenocytes led us to conclude that
an enzymatically active A subunit does no significantly change the
activation of antigen-specific CD4+ T cell responses. On the other
hand, s.c. administration of LT derivatives significantly changed
the induced immune response to a more biased Th2 response. This
result led us to investigate the activation of DCs in mice following
exposure to different LT derivatives.
The enzymatic activity of LT2 affected the activation of mouse
DCs, as demonstrated by the migratory behavior to the drain-
ing lymph nodes and enhanced expression of activation markers
(CD80 and CD86). DCs have the unique ability to internalize
protein antigens, migrate into draining lymph nodes, process and
present processed epitopes to naïve T lymphocytes. The adjuvant
activity of LT derivatives, similarly to that of cholera toxin and
other adjuvants, involves the recruitment and activation of DCs,
as demonstrated both under in vitro and in vivo conditions (24, 27,
28, 30, 32). Our results confirmed that, at the same concentrations,
LT1 and LT2 more efficiently activate DCs than LTK63, further
supporting the role of the ADP-ribosylation adjuvant activity. The
enzymatic activity of the A subunit was also linked to the local
transient inflammatory reactions observed in mice inoculated with
LT derivatives. Mice inoculated with LT1 or LT2 developed local
edema that persisted for some days after administration. Such
local reactions would probably contribute to the more efficient
activation of DCs and should not represent a serious obstacle for
future clinical testing, as demonstrated by the testing of LT using
the transcutaneous route (10, 11). Administration of LT1 and LT2
via the s.c. or i.d. routes would the inherent higher adjuvanticity
devoid of the risks involved with the mucosal administration of
these toxins.
The present study demonstrated unequivocally that LT2 pro-
moted high activation of CD8+ T lymphocytes as measured by the
number of IFN-γproducing T cells. The number of IFN-γproduc-
ing CD8 T cells correlated with the activation of antigen-specific
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CTL response suggesting that LT2, similarly to LT1, promote
the generation of multifunctional CD8+ effector T lymphocytes.
Inversely, mice immunized with LTK63 elicited a significant lower
activation of IFN-γ-producing CD8+ T cells and in vivo CTL
responses. Such differential adjuvant activity may correlate with
the lower migration of DCs for ILNs and lower expression of cos-
timulatory molecules observed in mice inoculated with LTK63
with regard to LTs with preserved enzymatic activity. Additionally,
these results indicated that, concerning activation of functional
CD8+ T cell responses, preservation of enzymatic activity of
LT has a relevant role in this adjuvant effect regardless of the
administration route.
Extensive clinical and experimental evidence supports the
notion that the activation of antigen-specific cytotoxic CD8+ T
cells is required for the efficient control of HIV or SIV infections
by promoting the clearance of infected cells (33–37). There is no
doubt that an efficient anti-HIV vaccine will require the coordi-
nate activation of B cells as well as CD4+ T and CD8+ T cells.
Previous reports have demonstrated that both toxic and non-toxic
LTs can induce antigen-specific CD8+ T cell responses following
mucosal administration (20, 38–41). The present results indicate
that LT2 shows strong adjuvant activity for a complete spectrum
of immune responses, particularly for functionally active CD8+ T
cells following administration via i.d. and s.c. routes. Our results
add further evidences that parenteral delivered LT-adjuvanted vac-
cines may represent a valuable alternative for activation of CD8+
T cell responses, particularly for diseases caused by viruses such
as HIV.
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GLOSSARY
ADJUVANT
Vaccine adjuvants are broadly defined as all components that
have functional ability to enhance in vivo immunogenicity of
the antigens. Basically there two categories: delivery systems,
that mainly function to co-localize vaccine components and to
target vaccines to antigen-presenting cells (APCs), as DC; and
immune potentiation. That directly activates immunological cells,
particularly APCs, through specific receptors.
CD4+ T CELLS OR T HELPER
The CD4+ T cells act of the activation, growth, and survival of
the other cell types, such as DC, B, and T cells. Further more,
these cells promote both changes on the antibody isotypes and
long-term memory. These cells secrete cytokines and chemokines
that modulate the immune response to bias Th1 or Th2 favor-
ing humoral or cellular, respectively. CD8+ T response antigen
requires CD4+ T cell help.
CD8+ T CELL-DEPENDENT CYTOTOXIC RESPONSE
Activated CD8+ T cells mediate their effector functions by direct
cytotoxicity and by secretion of cytokines such as IFN-γ. Rapid
death of target cells is induced by perforin-mediated transfer
of granzymes that initiate apoptosis. Slower killing is caused by
Fas ligand signaling to cells that express Fas. These cells are
pivotal for the clearance of a wide variety of pathogens and
tumors.
DENDRITIC CELLS
Dendritic cell are bone marrow-derived cells of rare frequency
but wide distribution in peripheral tissues. DC constantly sample
their environment but not necessarily initiating an immune reac-
tion until activation by a danger signal causes maturation, a state
characterized by increased expression of surface MHC and co-
stimulatory molecules, that results in increased ability to stimulate
T cells.
NON-TOXIC DERIVATIVES OF A REFERENCE LT
Site-directed mutagenesis permitted the generation of mutations
at the active site and resulted in full or partially non-toxic LT
forms which conserved adjuvanticity at the mucosal level. Among
these mutants, LTK63 shows a complete knockout of the enzy-
matic active after substitution of serine to lysine at position 63 of
the A subunit.
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